Prediction of contrast-induced nephropathy in patients with serum creatinine levels in the upper normal range by cystatin C: A prospective study in 374 patients

American Journal of Roentgenology

Volumn 202, Issue 2, 2014, Pages 452-458

  Wacker Gußmann, Annette ^a   Bühren, Katharina ^a   Schultheiss, Caroline ^a   Braun, Siegmund Lorenz ^b   Page, Sharon ^b   Saugel, Bernd ^a   Schmid, Sebastian ^a   Mair, Sebastian ^a   Schoemig, Albert ^a   Schmid, Roland M ^a   Huber, Wolfgang ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Contrast induced nephropathy (CIN); Coronary angiography; Creatinine; Cystatin C

Indexed keywords

CONTRAST MEDIUM; CREATININE; CYSTATIN C;

ADULT; AGE; AGED; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; BODY HEIGHT; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG ADMINISTRATION ROUTE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; UREA NITROGEN BLOOD LEVEL;

AGED; AREA UNDER CURVE; BLOOD UREA NITROGEN; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; CYSTATIN C; FEMALE; HUMANS; KIDNEY DISEASES; MALE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84892706406     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.10688     Document Type: Article

References (35)

1. Gonzalez F, Vincent F. Biomarkers for acute kidney injury in critically ill patients. Minerva Anestesiol 2012; 78:1394-1403
2. Shimizu A, Horikoshi S, Rinno H, Kobata M, Saito K, Tomino Y. Serum cystatin C may predict the early prognostic stages of patients with type 2 diabetic nephropathy. J Clin Lab Anal 2003; 17:164-167
3. Herget-Rosenthal S, Marggraf G, Hüsing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66:1115-1122
4. Newman DJ, Thakkar H, Edward RG, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47:312-318
5. Zhang Z, Lu B, Sheng X, Jin N. Cystatin C in prediction of acute kidney injury: a systemic review and meta-analysis. Am J Kidney Dis 2011; 58:356-365
6. Keller T, Messow CM, Lubos E, et al. Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the Atherogene Study. Eur Heart J 2009; 30:314-320
7. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radio labelled human cystatin C in the rat. Scand J Clin Lab Invest 1996; 56:409-414
8. Abrahamson M, Olafsson I, Palsdottir A, et al. Structure and expression of the human cystatin C gene. Biochem J 1990; 268:287-294
9. Inker LA, Schmid CH, Tighiouart H, et al.; CKDEPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367:20-29
10. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JJ. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74:243-248
11. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39:930-936
12. Levy EM, Viscoli CM, Horwitz RI. High mortality in contrast-associated renal failure is not explained by co-morbidity. (abstract) J Am Soc Nephrol 1996; 5(suppl):400
13. Harjai KJ, Raizada A, Shenoy C, et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol 2008; 101:812-819
14. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neil WW. Acute renal failure after coronary intervention: incidence, risk-factors, and relationship to mortality. Am J Med 1997; 103:368-375
15. McCullough PA, Stacul F, Becker CR, et al. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: executive summary. Rev Cardiovasc Med 2006; 7:177-197
16. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994; 331:1449-1450
17. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89:615-620
18. Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003; 91:1157-1162
19. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radio-graphic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343:180-184
20. Cigarroa RG, Lange RA, Williams RH, Hillis RD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86:649-652
21. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28:830-838
22. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53:766-772
23. Mehta RL, Kellum JA, Shah SV, et al.; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31
24. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44:1393-1399
25. Huber W, Jeschke B, Page M, et al. Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk. Intensive Care Med 2001; 27:1200-1209
26. Chew DP, Astley C, Molloy D, Vaile J, De Pasquale CG, Alyward P. Morbidity, mortality and economic burden of renal impairment in cardiac intensive care. Intern Med J 2006; 36:185-192
27. Polena S, Yang S, Alam R, et al. Nephropathy in critically ill patients without preexisting renal disease. Proc West Pharmacol Soc 2005; 48:134-135
28. Rashid AH, Brieva JL, Stokes B. Incidence of contrast-induced nephropathy in intensive care patients undergoing computerised tomography and prevalence of risk factors. Anaesth Intensive Care 2009; 37:968-975
29. Fujisawa N, Yashiro M, Segawa H, Kadoya Y, Kamata T. Discrepancy between cystatin C and creatinine points leading to a diagnosis of postrenal acute kidney injury and its reversibility: three case reports. Clin Exp Nephrol 2010; 14:608-613
30. Bellomo R, Kellum JA, Ronco C. Defining acute renal failure: physiological principles. Intensive Care Med 2004; 30:33-37
31. Tomino Y, Suzuki S, Gohda T, et al. Serum cystatin C may predict the prognostic stages of patients with IgA nephropathy prior to renal biopsy. J Clin Lab Anal 2001; 15:25-29
32. Rickli H, Benou K, Ammann P. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol 2004; 61:98-102
33. Shaker OG, El-Shehaby A, El-Khatib M. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiology 2010; 61:731-736
34. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-2264
35. Stevens LA, Padala S, Levey AS. Advances in glomerular filtration rate-estimating equations. Curr Opin Nephrol Hypertens 2010; 19:298-307